The microbiome can significantly impact the effectiveness of cancer therapies. For instance, certain gut bacteria can enhance the efficacy of immunotherapy by stimulating the immune system. Conversely, an imbalanced microbiome, or dysbiosis, may lead to increased treatment toxicity and reduced efficacy. Understanding these interactions helps in developing strategies to modulate the microbiome, thereby improving treatment outcomes.
